Tradition and toxicity: Evidential cultures in the kava safety debate

Social Studies of Science

Volumn 41, Issue 3, 2011, Pages 361-384

  Baker, Jonathan D ^a  

^a UNIVERSITY OF HAWAII   (United States)

Author keywords

Adverse drug reactions; Biocultural; Botanical medicines; Evidential cultures; Hepatotoxicity; Medical anthropology; Medicine evaluation; Risk assessment

Indexed keywords

KAVA;

ANTHROPOLOGY; ARTICLE; ETHNOPHARMACOLOGY; HERB DRUG INTERACTION; HERBAL MEDICINE; HUMAN; PHYTOTHERAPY; RISK ASSESSMENT; STANDARD; TOXIC HEPATITIS; TRADITIONAL MEDICINE; UNITED STATES;

ANTHROPOLOGY; DRUG-INDUCED LIVER INJURY; ETHNOPHARMACOLOGY; HAWAII; HERB-DRUG INTERACTIONS; HERBAL MEDICINE; HUMANS; KAVA; MEDICINE, TRADITIONAL; PHYTOTHERAPY; RISK ASSESSMENT;

EID: 79956225615     PISSN: 03063127     EISSN: 14603659     Source Type: Journal    
DOI: 10.1177/0306312710395341     Document Type: Article

References (56)

1. Abraham J. and Sheppard J. (1999) Complacent and conflicting scientific expertise in British and American drug regulation: Clinical risk assessment of Triazolam. Social Studies of Science 29(6): 803-843.
2. Adams V. (2002) Randomized controlled crime: Postcolonial sciences in alternative medicine research. Social Studies of Science 32(5/6): 659-690.
3. Baer HA (2001) Biomedicine and Alternative Healing Systems in America: Issues of Class, Race, Ethnicity, and Gender. Madison, WI: University of Wisconsin Press.
4. Baker J. (2008) Kava tradition and toxicity: Local and global discourses about the use and safety of Piper methysticum G. Forst (Piperaceae), an indigenous botanical undergoing pharmaceuticalization. Unpublished PhD dissertation, University of Hawai'i at Mānoa, Honolulu, Hawai'i.
5. Balick MJ and Lee R. (2002) Traditional use of Sakau (Kava) in Pohnpei: Lessons for integrative medicine. Alternative Therapies in Health and Medicine 8(4): 96-98.
6. Barguil Y., Mandeau A., Genelle B., Derycke T., Varra T.et al.(2001) Kava and gamma-glutamyl-transferase increase: Hepatic enzymatic induction of liver function alteration. British Medical Journal 322: 139.
7. Blumenthal M. (1998) Introduction. In: Blumenthal M, Busse WR, Goldberg A,et al.(eds) The Complete German Commission E Monographs. Austin, TX: American Botanical Council, 3-72.
8. Blumenthal M. (2002) Kava safety questioned due to case reports of liver toxicity. Herbalgram 55: 26-32.
9. Blumenthal M. (2005) German government reconsiders Kava. Herbalgram 67: 21-22.
10. Brown M. (2003) Aina under the influence: The criminalization of alcohol in 19th-century Hawaii. Theoretical Criminology 7: 89-110.
11. Bundesinstitut für und Medizinprodukte (2002) As Related to: Kava-Kava (Piper methysticum)-containing, and Kavain-Containing Drugs, Including Homeopathic Preparations with a Final Concentration up to, and Including D4. Bonn, Germany: BfArM.
12. Centre for Development of Enterprise (2006) Mission and Strategic Plan. Brussels: Centre for Development of Enterprise.
13. Chang H. (2003) UH scientist gets to the root of kava's reputation. The Star Bulletin, 23 April.
14. Chitturi S. and Farrell GC (2007) Drug-induced liver disease. In: Schiff ER, Sorrell MF and Maddrey WC (eds) Schiff's Diseases of the Liver. Philadelphia: Lippincott Williams and Wilkins, 923-1003.
15. Christl SU, Seifert A., and Seeler D. (2009) Toxic hepatitis after consumption of traditional kava preparation. Journal of Travel Medicine 16: 55-56.
16. Clough AR, Bailie RS, and Currie BJ (2003) Liver function test abnormalities in users of aqueous kava extracts. Journal of Toxicology - Clinical Toxicology 41: 821-829.
17. Collins HM (1981) Stages in the empirical programme of relativism. Social Studies of Science 11(1): 3-10.
18. Collins HM (1998) The meaning of data: Open and closed evidential cultures in the search for gravitational waves. American Journal of Sociology 104(2): 293-338.
19. Commission E (1990) Monograph: Piperis methystici rhizoma (Kava-Kava Wurzelstock), English translation. In: Blumenthal M, Busse WR, Goldberg A, Gruenwald J,et al.(eds) (1998) The Complete German Commission E Monographs. Austin, TX: American Botanical Council: 156-157.
20. Commission E (2002) Statement on Kava-Kava by the Members of the Commission E at the BfArM. Bonn, Germany: Commission E.
21. Daemmrich AA (2006) Pharmacopolitics: Drug Regulation in the United States and Germany. Chapel Hill: The University of North Carolina Press.
22. Denham A., McIntyre M., and Whitehouse J. (2002) Kava - the unfolding story: Report on a work-in-progress. Journal of Alternative and Complementary Medicine 8(3): 237-263.
23. Dragull K., Yoshida WY, and Tang C.-H(2003) Piperidine alkaloids from piper methysticum. Phytochemistry 63(2): 193-198.
24. Fiji Times (2005) Fiji takes kava ban fight to World Trade Organisation. Fiji Times, 20 July.
25. Finney BR (2003) The sin at Awarua. In: Finney BR, Sailing in the Wake of the Ancestors: Reviving Polynesian Voyaging. Honolulu, HI: Bishop Museum Press, 54-74.
26. Food Standards Australia New Zealand (2004) Kava: A Human Health Risk Assessment. Canberra: FSANZ.
27. Gieryn TF (1999) Cultural Boundaries of Science: Credibility on the Line. Chicago: University of Chicago Press.
28. Gruenwald J. (2007) The activities of the International Kava Executive Council (IKEC) to remove the kava ban in Europe. Unpublished presentation at the 2007 Hawai'i Pacific Islands Kava Festival, Honolulu, Hawai'i, 7 October.
29. Gruenwald J., Mueller C., and Skrabal J. (2003) Kava Report 2003: In-Depth Investigation into EU Member States Market Restrictions on Kava Products (Berlin, Germany: Phytopharm Consulting).
30. International Kava Executive Council (2008) Press Release: Lifting the German 'Ban' on Kava Exports: Outcome and Strategies of IKEC-EU Consultations. Brussels: IKEC.
31. Kaplowitz N. (2001) Drug-induced liver disorders: Implications for drug development and regulation. Drug Safety 24(7): 483-490.
32. Kim J. (2007) Alternative medicine's encounter with laboratory science: The scientific construction of Korean Medicine in a global age. Social Studies of Science 37: 855-880.
33. Lebot V., Merlin M. and Lindstrom L. (1992) Kava: The Pacific Drug. New Haven, CT: Yale University Press.
34. Lei SH (1999) From Changshan to a new anti-malarial drug: Re-networking Chinese drugs and excluding Chinese doctors. Social Studies of Science 29(3): 323-358.
35. Lim S., Dragull K., Tang C-S., Bittenbender H., Efird J. and Nerurkar PV (2007) Effects of kava alkaloid, pipermethystine, and kavalactones on oxidative stress and cytochrome P450 in F-344 rats, Toxicological Sciences 97: 214-221.
36. Loew D. and Gaus W. (2002) Kava-kava: Tagodie einer fehlbeurteilung [Kava-kava: The tragedy of a wrong judgement]. Zeitschrift fur Phytotherapie 23: 267-281.
37. Maddrey WC (2005) Drug-induced hepatotoxicity 2005. Journal of Clinical Gastroenterology 39(4): S83-S89.
38. Malani J.(2002) Evaluation of the Effects of Kava on the Liver. Suva, Fiji: Fiji School of Medicine.
39. Marks HM (1997) The Progress of Experiment: Science and Therapeutic Reform in the United States, 1900-1990. Cambridge: Cambridge University Press.
40. Medicines and Healthcare Products Regulatory Agency (2006) Report of the CSM's Expert Working Group on the Safety of Kava. London: MHRA.
41. Nerurkar PV, Dragull K. and Tang C-H. (2004) In vitro toxicity of kava alkaloid, pipermethystine, in HepG2 cells compared to kavalactones. Toxicological Sciences 79(1): 106-111.
42. Pacific Islands Forum Secretariat (2007) About Us. Suva, Fiji: Pacific Islands Forum Secretariat. Available at:
43. Petard (1826) Poivrier ava ou kawa piper methysticum. Journal de pharmacie [et de chime] [Paris] 12: 122-124.
44. Pittler MH and Ernst E. (2003) Kava extract versus placebo for treating anxiety (Review). The Cochrane Database of Systematic Reviews 1: CD003383.
45. Russmann S., Barguil Y., Cabalion P., Kritsanida M., Duhet D., and Lauterburg BH (2003) Hepatic injury due to traditional aqueous extracts of kava root in New Caledonia. European Journal of Gastroenterology & Hepatology 15: 1033-1036.
46. Schmidt M. (2003) ls kava really hepatotoxic? An analysis of the known data on adverse effects of kava preparations on the liver. Available at: www.uni-muenster.de/imperia/md/content/pharmazeutische_biologie/_v/revie w.pdf.
47. Schmidt M. and Nahrstedt A. (2002) Ist Kava lebertoxisch? Deutsche Apotheker Zeitung 127: 1006- 1020.
48. Shapin S. and Schaffer S. (1985) Leviathan and the Air-Pump: Hobbes, Boyle, and the Experimental Life. Princeton: Princeton University Press.
49. Singh YN (ed.) (2004) Kava: From Ethnology to Pharmacology. New York: CRC Press.
50. Starr P.(1982) The Social Transformation of American Medicine. New York: Basic Books.
51. Tavana G., Stewart P., Snyder S., Ragone D., Fredrickson K., Cox PA, and Borel J. (2003) Lack of evidence of kava-related hepatotoxicity in native populations in Savaii, Samoa. Herbalgram 59: 28-32.
52. Teschke R., Gaus W., and Loew D. (2003) Kava extracts: Safety and risks including rare hepatotoxicity. Phytomedicine 10: 440-446.
53. Waller DP (2002) Report on Kava and Liver Damage. Silver Spring, MD: American Herbal Products Association.
54. Willett K., Roth R., and Walker L. (2004) Workshop overview: Hepatotoxicity assessment for botanical dietary supplements. Toxicological Sciences 79: 4-9.
55. Winter K. (2004) Hawaiian 'awa (Piper methysticum): A study in ethnobotany. Unpublished MS Thesis, Department of Botany, University of Hawai'i at Mānoa, Honolulu, Hawaii.
56. World Health Organization (2007) Assessment of the Risk of Hepatotoxicity with Kava Products. Geneva: WHO.